poisar

Stocks · News reference

Beta Bionics Reports Third Quarter 2026 Financial Results and Updates Guidance

Fiscal.ai

Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolThe Motley Fool Team

    Beta Bio: 3 Key Takeaways for Long-Term Investors

    Beta Bio reported Q3 2026 net sales of $35.5 million with strong pharmacy channel momentum. The company received FDA clearance for Mint, its tubeless patch pump launching in Q1 2027, expected to drive significant growth. Management raised full-year 2026 revenue guidance and highlighted that Mint's gross margins could exceed current patch pump products within three years. The company is resubmitting its 3D Intelligence dosing algorithm application after addressing FDA feedback.

  2. Globenewswire IncKaplan Fox & Kilsheimer Llp

    Kaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to an Upcoming Deadline of November 3, 2026 in the Securities Class Action

    A securities class action lawsuit has been filed against Beta Bionics, Inc. for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious, life-threatening hypoglycemia incidents caused by device malfunctions in its iLet insulin pump, which were not properly disclosed. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about the severity of patient incidents. The deadline to move the court to become lead plaintiff is November 3, 2026.

  3. Globenewswire IncKahn Swick & Foti, Llc

    Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

    A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.